SCHEMBL4837579

SCHEMBL4837579

NC(C=O)C(c1ccc(Br)s1)N1CCN(C(=O)c2cc(F)ccc2C(F)(F)F)CC1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SCD O00767 4/20 0.38
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
RECQL P46063 1/20 0.34
HSD17B10 Q99714 1/20 0.34
EPHX2 P34913 1/20 0.34
SCN5A Q14524 2/20 0.33
SCN9A Q15858 2/20 0.33
GPR183 P32249 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
P2RX7 Q99572 1/20 0.33
KMT2A Q03164 1/20 0.32
MGLL Q99685 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776893 0.90 SCD (0.39) SCDPOLBHPGDRECQLHSD17B10
SCHEMBL4772658 0.81 CACNA2D1 (0.39) SCDHCRTR1HCRTR2EPHX2SCN5A
SCHEMBL4775889 0.80 SCN5A (0.42) SCDHCRTR1HCRTR2EPHX2SCN5A
SCHEMBL4753765 0.79 HCRTR1 (0.44) SCDHCRTR1HCRTR2SCN5ASCN9A
SCHEMBL4774662 0.79 CACNA1B (0.41) SCDHCRTR1HCRTR2POLBHPGD
Hydrochloric Acid SCHEMBL3466376 0.78 HCRTR1 (0.43) SCDHCRTR1HCRTR2SCN5ASCN9A
SCHEMBL4794877 0.75 HDAC8 (0.48) SCDHCRTR1HCRTR2POLBHPGD
SCHEMBL4780056 0.74 SCD (0.38) SCDHPGDMGLL
SCHEMBL4778154 0.72 ABL1 (0.34) RECQLHSD17B10KMT2AKDM4E
SCHEMBL4778523 0.72 SCD (0.40) SCDHSD17B10P2RX7MGLLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed